商品情報にスキップ
Glass vial labeled GLOW 70 mg, Batch No.002, expiration 07-08-2025, sealed with a gray cap and containing white lyophilized powder, photographed against a beige background. Ideal for peptide blends such as BPC-157, TB-500, and GHK-C
GLOW 70mg(10mg BPC157, 10mg TB500, 50mg GHK-CU)

GLOW 70mg(10mg BPC157, 10mg TB500, 50mg GHK-CU)

€115,00 EUR
税込。

                                              NOT FOR HUMAN CONSUMPTION

“GLOW” Peptide Blend (BPC-157 + TB-500 + GHK-Cu) 

Additional Benefits of a BPC-157 + TB-500 + GHK-Cu Blend Now Under Investigation

Benefit Key take-aways
1 Accelerated wound & incision healing BPC-157 and TB-500 promote angiogenesis, cell migration, and re-epithelialization; GHK-Cuboosts collagen I/III, GAGs, and MMP/TIMP balance—together shortening closure time and improving early tensile strength in models and small human series. <br/><em>Wound Repair & Regeneration; Burns; Journal of Dermatological Science</em>
2 Tendon/ligament repair BPC-157 up-regulates FAK/paxillin and VEGFR2/NO pathways; TB-500 enhances actin dynamicsand tenocyte migration—associated with better collagen alignment and load-to-failure in preclinical rotator cuff/Achilles/ACL models. <br/><em>American Journal of Sports Medicine; Journal of Orthopaedic Research</em>
3 Anti-inflammatory, pro-resolution effects All three peptides down-shift NF-κB/cytokines; palmitoylable copper peptide components (GHK-Cu) add SOD-mimetic/chelation—visible reductions in erythema and edema in cosmetic use. <br/><em>Skin Pharmacology & Physiology; Free Radical Biology & Medicine</em>
4 Scar quality & dermal remodeling GHK-Cu (with BPC-157/TB-500 angiogenesis) supports organized collagen, elastic fibers, and reduced hypertrophy risk; profilometry shows smoother texture in split-face studies. <br/><em>Clinical, Cosmetic & Investigational Dermatology; Experimental Dermatology</em>
5 Hair & scalp signals (adjunct) GHK-Cu may stimulate follicular ECM and peri-follicular microvasculature; BPC/TB-500 angiogenesis may complement microneedling/PRP protocols (cosmetic endpoints). <br/><em>Journal of Cosmetic Dermatology; Dermatologic Therapy</em>
6 GI mucosal protection (BPC-157) Robust rodent data show gastric/colonic ulcer healing, anastomosis strength, and reduced NSAID injury; clinical translation is ongoing. <br/><em>Gut; Pharmacological Reports</em>
7 Nerve/axon support BPC-157 and TB-500 improve axonal outgrowth and Schwann-cell migration in models—early signals for neuropathic recovery; human evidence limited. <br/><em>Frontiers in Neuroscience; Neuroscience</em>
8 Post-procedure “glow” & downtime Topical meso/serum GHK-Cu-forward blends reduce post-laser/needling redness and speed visual recovery when used per provider protocol. <br/><em>Journal of Cosmetic Dermatology; Aesthetic Surgery Journal</em>
9 Synergy with rehab Pairing BPC-157/TB-500 (matrix & angiogenesis) with progressive loading and adequate proteinappears additive in translational paradigms for function and pain reduction. <br/><em>Sports Medicine; Journal of Physiology</em>

2. Molecular Mechanism of Action

2.1 Pharmacodynamics (by component)

  • BPC-157: Modulates VEGFR2/NO and FAK–paxillin signaling → angiogenesis, cell migration, tight-junctionand mucosal repair; anti-inflammatory via NF-κB restraint.

  • TB-500 (Tβ4 fragment): G-actin sequestration → cell motility, lamellipodia formation; up-regulates VEGF/ILK/integrins; anti-apoptotic and pro-angiogenic in injury beds.

  • GHK-Cu: Copper-bound tripeptide that shifts TGF-β/SMAD, MMP/TIMP and HIF-1/VEGF axes; increases collagen/elastin and keratinocyte migration; antioxidant/chelating activity.

2.2 Down-stream Biology

Pathway Functional outcome Context
VEGF/VEGFR2 → eNOS/NO Microvascular growth, perfusion Wounds, tendon/ligament
FAK–paxillin–integrins Adhesion/migration, matrix attachment Soft-tissue repair
Actin remodeling (TB-500) Rapid cell motility, re-epithelialization Dermis/tenocytes
TGF-β/SMAD, MMP/TIMP (GHK-Cu) Balanced remodeling, scar quality Dermis/ECM
NF-κB restraint ↓ TNF-α/IL-1β/IL-6 Inflamed tissue/mucosa

3. Pharmacokinetics

  • Routes used:

    • Topical/mesotherapy (face/scars/scalp) with GHK-Cu-dominant content;

    • Local/peri-lesional injections for soft-tissue research protocols (BPC-157/TB-500).

  • Half-lives: Short peptides (minutes–hours) locally; GHK-Cu binds skin proteins and persists longer in upper dermis.

  • Penetration/stability: Improved by palmitoylation, liposomes, or microneedling; copper peptides are pH/oxidation-sensitive (avoid peroxides/strong acids in the same step).

  • Systemic exposure: Low with topical; higher with injections—formal human PK is limited for BPC-157/TB-500.

4. Pre-clinical and Translational Evidence

  • Wound/tendon/ligament: Multiple animal studies show faster closure, greater tensile strength, and better collagen orientation with BPC-157 and TB-500; GHK-Cu adds dermal matrix quality and antioxidant effects.

  • GI: BPC-157 robustly protects gastric/colonic tissue against toxins/NSAIDs and improves anastomosis healing in rodents.

  • Neuro: Axon outgrowth and functional recovery signals appear in nerve-injury models.

  • Aesthetic skin: Split-face/topical studies with GHK-Cu demonstrate improvements in wrinkle depth, elasticity, TEWL, and tone over 8–12 weeks.

Evidence quality note: GHK-Cu has human cosmetic data; BPC-157/TB-500 data are mostly preclinicalwith limited, heterogeneous human reports. High-quality RCTs for the combination are lacking.

5. Emerging Clinical Interests

Field Rationale Status
Chronic wounds/DFU/VLU Angiogenesis + remodeling Pilot/observational
Tendinopathy/ligament sprain Matrix alignment + cell migration Translational/feasibility
Post-procedure aesthetics Redness down, texture up (GHK-Cu) Small cosmetic studies
Post-op scars Balanced MMP/TIMP + perfusion Early programs
GI mucosa (BPC-157) Ulcer/NSAID/inflammation protection Preclinical → exploratory
Peripheral nerve Axon/Schwann support Preclinical

6. Safety and Tolerability

  • Common (topical): Mild stinging, transient erythema/itch; rare contact sensitivity to copper or excipients.

  • Injection-site (research use): Bruising, tenderness, hematoma; infection risk if asepsis lapses.

  • Systemic/theoretical:

    • Pro-angiogenic caution in active malignancy or proliferative retinopathies (theoretical risk).

    • Copper: avoid over-layering with strong acids/oxidizers; rare allergic or blue-green discoloration on fabrics.

    • BPC-157/TB-500: Sparse human safety datasets; avoid in pregnancy/breastfeeding and serious comorbidity outside trials.

  • Sport/anti-doping: BPC-157 and TB-500 are prohibited (non-approved peptides/growth factors).

  • Drug interactions: None well characterized; caution with anti-VEGF therapies or anticoagulation (procedure-related bleeding risk).

Comparative safety matrix

Feature GHK-Cu (topical) BPC-157 (inj/topical) TB-500 (inj)
Regulatory use Cosmetic ingredient Research chemical Research chemical
Human evidence Cosmetic RCTs/split-face Limited Limited
Main risks Mild irritation; copper sensitivity Unknown systemic; site reactions Unknown systemic; site reactions
Pro-angiogenic Mild/local Yes (models) Yes (models)

7. Regulatory Landscape

  • GHK-Cu: Used legally in cosmetics/OTC topicals (appearance claims only).

  • BPC-157 & TB-500: Not approved as medicines; research-only status; WADA-prohibited.

  • Compounding: Clinic “GLOW” blends vary in identity/purity; no standardized monograph or dosing exists.

8. Practical Use & Future Directions

  • If used cosmetically (topical):

    • AM: gentle cleanse → antioxidant → GHK-Cu serum → moisturizer → broad-spectrum SPF.

    • PM: cleanse → GHK-Cu serum → peptide moisturizer; separate from strong acids/peroxides.

  • If studied for soft-tissue repair (research settings): Pair with graded loading/physiotherapy, protein 1.6–2.2 g/kg/d, vitamin C, and sleep optimization; track pain/function and tendon imaging.

  • Research needs: Randomized, controlled trials on the combination, standardized dose/route and quality, tendon/wound biomechanics, and safety (angiogenesis-related, systemic labs).

Selected References

  • Wound Repair & Regeneration; Burns; Journal of Dermatological Science — Dermal healing, collagen organization, and angiogenesis under BPC-157/TB-500/GHK-Cu paradigms.

  • American Journal of Sports Medicine; Journal of Orthopaedic Research — Tendon/ligament models: load-to-failure, collagen alignment, mechanosignaling.

  • Skin Pharmacology & Physiology; Clinical, Cosmetic & Investigational Dermatology — GHK-Cu cosmetic trials (wrinkles, elasticity, TEWL, redness).

  • Free Radical Biology & Medicine; Oxidative Medicine and Cellular Longevity — Copper-peptide antioxidant/chelating behavior and redox biology.

  • Gut; Pharmacological Reports — BPC-157 gastroprotection/anastomosis strength in preclinical studies.

  • Frontiers in Neuroscience; Neuroscience — Axonal outgrowth and neurorepair signals with BPC-157/Tβ4 derivatives.

  • Sports Medicine; Journal of Physiology — Rehab synergy with matrix/angiogenic cues